Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -37.49 Billion KRW | -2519.98% |
| 2022 | 1.54 Billion KRW | -72.44% |
| 2021 | 5.62 Billion KRW | 863.23% |
| 2020 | 583.64 Million KRW | -93.88% |
| 2019 | 9.53 Billion KRW | -72.85% |
| 2018 | 35.12 Billion KRW | 357.62% |
| 2017 | 7.67 Billion KRW | -10.11% |
| 2016 | 8.53 Billion KRW | -63.33% |
| 2015 | 23.28 Billion KRW | -17.88% |
| 2014 | 28.35 Billion KRW | 23.34% |
| 2013 | 22.99 Billion KRW | 7.24% |
| 2012 | 21.44 Billion KRW | 191.7% |
| 2011 | 7.35 Billion KRW | -81.25% |
| 2010 | 39.19 Billion KRW | 0.3% |
| 2009 | 39.07 Billion KRW | -0.45% |
| 2008 | 39.25 Billion KRW | -7.55% |
| 2007 | 42.45 Billion KRW | 60.24% |
| 2006 | 26.49 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 3.17 Billion KRW | 224.76% |
| 2024 Q1 | -1.62 Billion KRW | 89.64% |
| 2024 Q2 | -2.54 Billion KRW | -56.51% |
| 2023 Q1 | -4.68 Billion KRW | -228.59% |
| 2023 FY | -37.49 Billion KRW | -2519.98% |
| 2023 Q2 | -895.2 Million KRW | 80.9% |
| 2023 Q3 | -16.2 Billion KRW | -1710.02% |
| 2023 Q4 | -15.71 Billion KRW | 3.03% |
| 2022 Q2 | -558.92 Million KRW | 71.8% |
| 2022 Q1 | -1.98 Billion KRW | -137.0% |
| 2022 FY | 1.54 Billion KRW | -72.44% |
| 2022 Q3 | -1.33 Billion KRW | -138.65% |
| 2022 Q4 | 3.64 Billion KRW | 373.21% |
| 2021 FY | 5.62 Billion KRW | 863.23% |
| 2021 Q1 | -2.08 Billion KRW | -197.96% |
| 2021 Q3 | 2.99 Billion KRW | 565.88% |
| 2021 Q2 | -642.62 Million KRW | 69.19% |
| 2021 Q4 | 5.35 Billion KRW | 78.92% |
| 2020 Q1 | 756.38 Million KRW | -87.64% |
| 2020 Q3 | 102.52 Million KRW | -90.14% |
| 2020 Q4 | 2.12 Billion KRW | 1976.73% |
| 2020 Q2 | 1.03 Billion KRW | 37.49% |
| 2020 FY | 583.64 Million KRW | -93.88% |
| 2019 Q3 | -2.08 Billion KRW | -154.2% |
| 2019 Q4 | 6.11 Billion KRW | 393.98% |
| 2019 Q1 | 1.65 Billion KRW | 574.56% |
| 2019 FY | 9.53 Billion KRW | -72.85% |
| 2019 Q2 | 3.84 Billion KRW | 131.6% |
| 2018 FY | 35.12 Billion KRW | 357.62% |
| 2018 Q3 | 29.5 Billion KRW | 684.22% |
| 2018 Q4 | 245.85 Million KRW | -99.17% |
| 2018 Q2 | 3.76 Billion KRW | 133.83% |
| 2018 Q1 | 1.6 Billion KRW | 102.15% |
| 2017 Q3 | 3.7 Billion KRW | 1059.49% |
| 2017 Q1 | 2.85 Billion KRW | 289.28% |
| 2017 Q2 | 319.61 Million KRW | -88.8% |
| 2017 FY | 7.67 Billion KRW | -10.11% |
| 2017 Q4 | 796.05 Million KRW | -78.52% |
| 2016 Q3 | -427.36 Million KRW | -107.86% |
| 2016 FY | 8.53 Billion KRW | -63.33% |
| 2016 Q2 | 5.43 Billion KRW | 94.19% |
| 2016 Q4 | 733.22 Million KRW | 271.57% |
| 2016 Q1 | 2.79 Billion KRW | -40.43% |
| 2015 Q4 | 4.69 Billion KRW | -22.35% |
| 2015 Q2 | 5.7 Billion KRW | -16.59% |
| 2015 FY | 23.28 Billion KRW | -17.88% |
| 2015 Q3 | 6.05 Billion KRW | 6.09% |
| 2015 Q1 | 6.83 Billion KRW | 30.18% |
| 2014 Q4 | 5.25 Billion KRW | -31.16% |
| 2014 Q2 | 6.97 Billion KRW | -17.89% |
| 2014 Q1 | 8.49 Billion KRW | 34.67% |
| 2014 Q3 | 7.62 Billion KRW | 9.33% |
| 2014 FY | 28.35 Billion KRW | 23.34% |
| 2013 Q4 | 6.31 Billion KRW | -10.26% |
| 2013 FY | 22.99 Billion KRW | 7.24% |
| 2013 Q2 | 6.31 Billion KRW | 89.46% |
| 2013 Q1 | 3.33 Billion KRW | -58.42% |
| 2013 Q3 | 7.03 Billion KRW | 11.33% |
| 2012 Q2 | 4.8 Billion KRW | 18019.02% |
| 2012 Q3 | 8.59 Billion KRW | 78.76% |
| 2012 FY | 21.44 Billion KRW | 191.7% |
| 2012 Q1 | 26.52 Million KRW | 0.0% |
| 2012 Q4 | 8.01 Billion KRW | -6.67% |
| 2011 Q3 | 5.47 Billion KRW | -21.65% |
| 2011 Q2 | 6.98 Billion KRW | -54.08% |
| 2011 Q1 | 15.21 Billion KRW | 105.69% |
| 2011 FY | 7.35 Billion KRW | -81.25% |
| 2010 FY | 39.19 Billion KRW | 0.3% |
| 2010 Q3 | 10.3 Billion KRW | 64.33% |
| 2010 Q4 | 7.39 Billion KRW | -28.2% |
| 2010 Q2 | 6.27 Billion KRW | -27.76% |
| 2010 Q1 | 8.67 Billion KRW | -25.35% |
| 2009 Q4 | 11.62 Billion KRW | 20.62% |
| 2009 FY | 39.07 Billion KRW | -0.45% |
| 2009 Q1 | - KRW | -100.0% |
| 2009 Q2 | 9.12 Billion KRW | 0.0% |
| 2009 Q3 | 9.63 Billion KRW | 5.59% |
| 2008 FY | 39.25 Billion KRW | -7.55% |
| 2008 Q2 | 8.83 Billion KRW | 0.0% |
| 2008 Q3 | 10.88 Billion KRW | 23.22% |
| 2008 Q4 | 8.21 Billion KRW | -24.57% |
| 2008 Q1 | - KRW | -100.0% |
| 2007 Q2 | 8.56 Billion KRW | 0.0% |
| 2007 Q4 | 13.15 Billion KRW | 6.44% |
| 2007 FY | 42.45 Billion KRW | 60.24% |
| 2007 Q3 | 12.35 Billion KRW | 44.23% |
| 2006 FY | 26.49 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 10386.13% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 148.772% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 52.871% |
| HANDOK Inc. | 12.57 Billion KRW | 398.094% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -1785.071% |
| Yuhan Corporation | 74.56 Billion KRW | 150.289% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 435.438% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | -107.824% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 116.674% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 1326.964% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 361.294% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 6387.154% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 3990.653% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 238.715% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 10386.13% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -383.452% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 1029.603% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 46.395% |
| JW Holdings Corporation | 143.66 Billion KRW | 126.1% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 29.804% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 115.206% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 137.383% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 20.88% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 641.319% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 679.456% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 529.448% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 10386.13% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 176.889% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 128.107% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 137.383% |
| Yuhan Corporation | 74.56 Billion KRW | 150.289% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 279.237% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 1302.824% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 187.212% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 137.383% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 283.051% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 168.238% |
| CKD Bio Corp. | -20.15 Billion KRW | -86.065% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 216.331% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 248.196% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 215.286% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 20.88% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 213.123% |
| Boryung Corporation | 68.26 Billion KRW | 154.927% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 361.294% |
| JW Lifescience Corporation | 32.09 Billion KRW | 216.843% |